BTCC / BTCC Square / Global Cryptocurrency /
Eli Lilly Rises on VERVE-102 Gene Therapy’s LDL-C Reduction

Eli Lilly Rises on VERVE-102 Gene Therapy’s LDL-C Reduction

Global Cryptocurrency
Release Time:
2026-05-26 04:31:02
0
BTCCSquare news:

Eli Lilly shares climbed 2.24% to $1,065.00 after interim Phase 1b data showed VERVE-102, a one-time gene editing therapy, achieved durable LDL-C reductions. The treatment targets PCSK9 in the liver via in vivo base editing, demonstrating dose-dependent efficacy—88% PCSK9 reduction and 62% LDL-C drop at the highest dose.

Results from the Heart-2 trial, involving 35 adults with heterozygous familial hypercholesterolemia or premature coronary artery disease, were presented at the European Atherosclerosis Society Congress. Safety data supported further development, positioning Lilly competitively in cardiovascular gene therapies.

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users